223 related articles for article (PubMed ID: 38543739)
21. Advances in the Study of Antitumour Immunotherapy for Newcastle Disease Virus.
Meng Q; He J; Zhong L; Zhao Y
Int J Med Sci; 2021; 18(11):2294-2302. PubMed ID: 33967605
[TBL] [Abstract][Full Text] [Related]
22. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL.
Kazimirsky G; Jiang W; Slavin S; Ziv-Av A; Brodie C
Stem Cell Res Ther; 2016 Oct; 7(1):149. PubMed ID: 27724977
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the in vitro and in vivo effect of liposomal doxorubicin along with oncolytic Newcastle disease virus on 4T1 cell line: Animal preclinical research.
Faranoush P; Jahandideh A; Nekouian R; Mortazavi P
Vet Med Sci; 2023 May; 9(3):1426-1437. PubMed ID: 36920334
[TBL] [Abstract][Full Text] [Related]
24. [Progress in using Newcastle disease virus for tumor therapy: a review].
Wu Y; Hao J; Li D
Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105
[TBL] [Abstract][Full Text] [Related]
25. Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.
Ricca JM; Oseledchyk A; Walther T; Liu C; Mangarin L; Merghoub T; Wolchok JD; Zamarin D
Mol Ther; 2018 Apr; 26(4):1008-1019. PubMed ID: 29478729
[TBL] [Abstract][Full Text] [Related]
26. [Expressing foreign genes by Newcastle disease virus for cancer therapy].
Bai FL; Tian H; Yu QZ; Renl GP; Li DS
Mol Biol (Mosk); 2015; 49(2):195-204. PubMed ID: 26065249
[TBL] [Abstract][Full Text] [Related]
27. Combined oncolytic virotherapy gold nanoparticles as synergistic immunotherapy agent in breast cancer control.
Jabir MS; Al-Shammari AM; Ali ZO; Albukhaty S; Sulaiman GM; Jawad SF; Hamzah SS; Syed A; Elgorban AM; Eswaramoorthy R; Zaghloul NSS; Al-Dulimi AG; Najm MAA
Sci Rep; 2023 Oct; 13(1):16843. PubMed ID: 37803068
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Newcastle disease virus mediated dendritic cell activation and cross-priming tumor-specific immune responses ex vivo.
Xu Q; Rangaswamy US; Wang W; Robbins SH; Harper J; Jin H; Cheng X
Int J Cancer; 2020 Jan; 146(2):531-541. PubMed ID: 31584185
[TBL] [Abstract][Full Text] [Related]
29. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma.
Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J
J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179
[TBL] [Abstract][Full Text] [Related]
30. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the oncolytic potential of R
Sharma KK; Kalyani IH; Mohapatra J; Patel SD; Patel DR; Vihol PD; Chatterjee A; Patel DR; Vyas B
Arch Virol; 2017 Sep; 162(9):2705-2713. PubMed ID: 28578522
[TBL] [Abstract][Full Text] [Related]
32. Newcastle disease virus degrades HIF-1α through proteasomal pathways independent of VHL and p53.
Abd-Aziz N; Stanbridge EJ; Shafee N
J Gen Virol; 2016 Dec; 97(12):3174-3182. PubMed ID: 27902314
[TBL] [Abstract][Full Text] [Related]
33. Targeting aerobic glycolysis by dichloroacetate improves Newcastle disease virus-mediated viro-immunotherapy in hepatocellular carcinoma.
Meng G; Li B; Chen A; Zheng M; Xu T; Zhang H; Dong J; Wu J; Yu D; Wei J
Br J Cancer; 2020 Jan; 122(1):111-120. PubMed ID: 31819179
[TBL] [Abstract][Full Text] [Related]
34. Cell-type-specific innate immune response to oncolytic Newcastle disease virus.
Biswas M; Kumar SR; Allen A; Yong W; Nimmanapalli R; Samal SK; Elankumaran S
Viral Immunol; 2012 Aug; 25(4):268-76. PubMed ID: 22808996
[TBL] [Abstract][Full Text] [Related]
35. Systemic cellular viroimmunotherapy for canine high-grade gliomas.
Cloquell A; Mateo I; Gambera S; Pumarola M; Alemany R; García-Castro J; Perisé-Barrios AJ
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600663
[TBL] [Abstract][Full Text] [Related]
36. The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model.
He J; An Y; Qi J; Cui L; Yang K; Liu M; Qu B; Yan S; Yin J; Jing X; Dong H; Yu Q; Li D; Wu Y
J Med Virol; 2021 Jun; 93(6):3890-3898. PubMed ID: 32779745
[TBL] [Abstract][Full Text] [Related]
37. Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation.
Vijayakumar G; Zamarin D
Methods Mol Biol; 2020; 2058():133-154. PubMed ID: 31486036
[TBL] [Abstract][Full Text] [Related]
38. Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.
Koks CA; Garg AD; Ehrhardt M; Riva M; Vandenberk L; Boon L; De Vleeschouwer S; Agostinis P; Graf N; Van Gool SW
Int J Cancer; 2015 Mar; 136(5):E313-25. PubMed ID: 25208916
[TBL] [Abstract][Full Text] [Related]
39. Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion.
García-Romero N; Palacín-Aliana I; Esteban-Rubio S; Madurga R; Rius-Rocabert S; Carrión-Navarro J; Presa J; Cuadrado-Castano S; Sánchez-Gómez P; García-Sastre A; Nistal-Villan E; Ayuso-Sacido A
Cells; 2020 Jun; 9(6):. PubMed ID: 32516884
[TBL] [Abstract][Full Text] [Related]
40. Safety and clinical usage of newcastle disease virus in cancer therapy.
Lam HY; Yeap SK; Pirozyan MR; Omar AR; Yusoff K; Suraini AA; Abd-Aziz S; Alitheen NB
J Biomed Biotechnol; 2011; 2011():718710. PubMed ID: 22131816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
